Glenmark Pharmaceuticals sees potential of NONS to prevent Covid-19

Glenmark Pharmaceuticals plans to test its upcoming nitric oxide nasal spray (NONS) that it has licensed from a Canadian Biotech firm as a preventive measure for Covid-19.
 
The firm, which has tasted success with its oral antiviral drug favipiravir, is now betting on the NONS to drive revenues from its Covid-19 portfolio.
 
In the first quarter, Covid-19 revenues were a tad less than 10 per cent of Glenmark’s turnover. Favipiravir alone sold for around Rs 350 crore, boosting its India business by 57 per cent year-on-year (YoY). What’s more? Fabiflu (Glenmark’s brand of favipiravir) enjoys margins of 35